Argus upgrades ELV to Buy with $510 target
Alpha Vantage · TradingView · · AI-summarised by FinFlash
Argus Research has upgraded Elevance Health (ELV) to Buy from Hold, setting a price target of $510. This target suggests a 17.5% upside from the stock's closing price of $433.93 on November 17. Recent analyst actions on Elevance Health have seen price targets ranging from $449 to $523 over the past month.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.